Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction
Thomas A. Gaziano, Gregg C. Fonarow, Eric J. Velazquez, et al.
JAMA Cardiology (2020) Vol. 5, Iss. 11, pp. 1236-1236
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Circulation (2022) Vol. 145, Iss. 18
Open Access | Times Cited: 3102
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 17, pp. e263-e421
Open Access | Times Cited: 1551
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Circulation (2022) Vol. 145, Iss. 18
Open Access | Times Cited: 645
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 17, pp. 1757-1780
Open Access | Times Cited: 594
Economic Issues in Heart Failure in the United States
Paul A. Heidenreich, Gregg C. Fonarow, Yekaterina Opsha, et al.
Journal of Cardiac Failure (2022) Vol. 28, Iss. 3, pp. 453-466
Open Access | Times Cited: 98
2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Journal of Cardiac Failure (2022) Vol. 28, Iss. 5, pp. 810-830
Closed Access | Times Cited: 76
An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction
Larry A. Allen, Grace Venechuk, Colleen K. McIlvennan, et al.
Circulation (2020) Vol. 143, Iss. 5, pp. 427-437
Open Access | Times Cited: 123
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Kamil F. Faridi, Elias J. Dayoub, Joseph S. Ross, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 25, pp. 2516-2525
Open Access | Times Cited: 47
Financial Toxicity of Medical Management of Heart Failure
Smrithi Sukumar, Jason H. Wasfy, James L. Januzzi, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 20, pp. 2043-2055
Open Access | Times Cited: 26
Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure
Anthony P. Carnicelli, Steven Lippmann, Stephen J. Greene, et al.
Journal of Cardiac Failure (2021) Vol. 27, Iss. 8, pp. 826-836
Closed Access | Times Cited: 45
Expenditure on Heart Failure in the United States
Roshni Bhatnagar, Gregg C. Fonarow, Paul A. Heidenreich, et al.
JACC Heart Failure (2022) Vol. 10, Iss. 8, pp. 571-580
Open Access | Times Cited: 31
The economics of heart failure care
Wei Chen, Paul A. Heidenreich, Alexander T. Sandhu
Progress in Cardiovascular Diseases (2024) Vol. 82, pp. 90-101
Open Access | Times Cited: 5
2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure
M. Kittleson, Khadijah Breathett, Boback Ziaeian, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 12, pp. 1123-1143
Closed Access | Times Cited: 5
2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures
M. Kittleson, Khadijah Breathett, Boback Ziaeian, et al.
Circulation Cardiovascular Quality and Outcomes (2024) Vol. 17, Iss. 9
Closed Access | Times Cited: 5
Treatment of HF in an Era of Multiple Therapies
Ankeet S. Bhatt, William T. Abraham, JoAnn Lindenfeld, et al.
JACC Heart Failure (2020) Vol. 9, Iss. 1, pp. 1-12
Open Access | Times Cited: 33
Reply
Hyukjin Park, Nuri Lee, Hyun Yoon
JACC CardioOncology (2025) Vol. 7, Iss. 2, pp. 190-190
Open Access
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
Adnan Alsumali, Laurence Djatche, Andrew Briggs, et al.
PharmacoEconomics (2021) Vol. 39, Iss. 11, pp. 1343-1354
Open Access | Times Cited: 26
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management
Ankeet S. Bhatt, Muthiah Vaduganathan, Brian Claggett, et al.
JAMA Cardiology (2023) Vol. 8, Iss. 11, pp. 1041-1041
Closed Access | Times Cited: 10
Budget impact analyses for treatment of heart failure. A systematic review
Abedin Teimourizad, Abdosaleh Jafari, Firooz Esmaeilzadeh
Heart Failure Reviews (2024) Vol. 29, Iss. 4, pp. 785-797
Closed Access | Times Cited: 3
Health Care Spending After Initiating Sacubitril-Valsartan vs Renin-Angiotensin System Blockers for Heart Failure Treatment
Catherine S. Hwang, Rishi Desai, Aaron S. Kesselheim, et al.
JAMA Health Forum (2025) Vol. 6, Iss. 2, pp. e245385-e245385
Open Access
Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization
Neal M. Dixit, Shivani Shah, Boback Ziaeian, et al.
US Cardiology Review (2021) Vol. 15
Open Access | Times Cited: 23
Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population‐based cohort study of >25 000 Medicare beneficiaries
Ankeet S. Bhatt, Muthiah Vaduganathan, Scott D. Solomon, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 9, pp. 1506-1515
Closed Access | Times Cited: 15
Relation of Household Income to Access and Adherence to Combination Sacubitril/Valsartan in Heart Failure: A Retrospective Analysis of Commercially Insured Patients
Amber E. Johnson, Gretchen Swabe, Daniel Addison, et al.
Circulation Cardiovascular Quality and Outcomes (2022) Vol. 15, Iss. 7
Open Access | Times Cited: 13
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials
Ankeet S. Bhatt, Muthiah Vaduganathan, Brian Claggett, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 5
Open Access | Times Cited: 2
Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients
Egle Corrado, Giuseppe Dattilo, Giuseppe Coppola, et al.
European Journal of Clinical Pharmacology (2021) Vol. 78, Iss. 1, pp. 19-25
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top